Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 13.07.2026 3 BJU Int 1 BMC Urol 1 Br J Cancer 2 Cancer Imaging 2 Eur Radiol 1 Eur Urol 1 Int J Urol 2 J Clin Oncol 3 J Urol 1 Nat Rev Urol 1 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Prostate 1 Ther Adv Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. AL-KHANATY A, McGrath S, Dinneen E, Qin K, et al
   Subcutaneous local anaesthetic after transperineal prostate biopsy under general anaesthesia: a randomised trial.
   BJU Int. 2026;138 Suppl 2:S64-S73.
   PubMed         Abstract available
   
   
2. XU Y, Hu D, Ruan Y
   Comment on 'Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience'.
   BJU Int. 2026 Jul 10. doi: 10.1111/bju.70369.
   PubMed        
   
   
3. CANNOLETTA D, Brembilla G, Longoni M, Porzi ME, et al
   Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.
   BJU Int. 2026 Jul 8. doi: 10.1111/bju.70373.
   PubMed         Abstract available
   
   

   
   BMC Urol

4. FU J, Zhou X, Liu Y, Deng H, et al
   Added value of PHI in predicting lymph node invasion in prostate cancer: an external validation.
   BMC Urol. 2026;26:159.
   PubMed         Abstract available
   
   

   
   Br J Cancer

5. ELSESY ME, Moustafa A, Oh-Hohenhorst SJ, Muller C, et al
   Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status.
   Br J Cancer. 2026 Jul 7. doi: 10.1038/s41416-026-03518.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

6. PONSIGLIONE A, Schoots IG, Padhani AR
   The evolving PI-RADS paradigm.
   Cancer Imaging. 2026;26:86.
   PubMed         Abstract available
   
   
7. HONG DS, Wu XH, Ruan CX, Pan DS, et al
   Preoperative dual-ROI mpMRI radiomics integrating intratumoral and periprostatic adipose tissue features with clinical factors for predicting positive surgical margins after radical prostatectomy.
   Cancer Imaging. 2026;26:85.
   PubMed         Abstract available
   
   

   
   Eur Radiol

8. VAN LOHUIZEN Q, Fransen SJ, Yiasemis G, Twilt JJ, et al
   Diagnostic assessment of artificial intelligence reconstruction on accelerated prostate MRI: a retrospective, paired, multi-reader multi-case study.
   Eur Radiol. 2026;36:6440-6449.
   PubMed         Abstract available
   
   
9. GOEDEGEBUURE EP, Boellaard TN, van Dijk-de Haan MC, Heijmink SWTPJ, et al
   Improving membranous urethral length measurements on prostate MRI: a comparison of online training methods.
   Eur Radiol. 2026;36:6419-6427.
   PubMed         Abstract available
   
   

   
   Eur Urol

10. STABILE A, Montorsi F
    Focal Therapy for Localized Prostate Cancer: Maturing Evidence, Evolving Questions.
    Eur Urol. 2026 Jul 7:S0302-2838(26)02236-0. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Urol

11. ELTING L, Almohtasib J, Francisco IFS, Perez-Londono A, et al
    Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.
    Int J Urol. 2026;33:e70568.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

12. MORRIS MJ, Armstrong AJ
    Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jul 9:JCO2601356. doi: 10.1200/JCO-26-01356.
    PubMed        
    
    
13. TURCO F, Gillessen S, Tombal B
    PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jul 9:JCO2600631. doi: 10.1200/JCO-26-00631.
    PubMed        
    
    

    
    J Urol

14. SHORE ND, Gleave M, De Giorgi U, Rannikko A, et al
    Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.
    J Urol. 2026;216:311.
    PubMed        
    
    
15. SHORE ND, De Giorgi U, Tutrone RF, Bailen JL, et al
    Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.
    J Urol. 2026;216:311.
    PubMed        
    
    
16. PRESTI J JR, Prausnitz S, Altschuler A, Horton B, et al
    Informed Decision Making for Prostate Cancer Screening - A Prospective, Randomized Study of Two Novel Web-based, Electronic Visits.
    J Urol. 2026 Jul 8:101097JU0000000000005205. doi: 10.1097/JU.0000000000005205.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

17. FLETCHER SA, Pickersgill NA, Osorio JC, McHugh DJ, et al
    Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.
    Nat Rev Urol. 2026 Jul 9. doi: 10.1038/s41585-026-01172.
    PubMed         Abstract available
    
    

    
    Oncogene

18. CONG H, Seilani F, Goettl R, He D, et al
    SETDB1-mediated repression of RhoB promotes EMT and metastatic progression in prostate cancer.
    Oncogene. 2026 Jul 8. doi: 10.1038/s41388-026-03893.
    PubMed         Abstract available
    
    

    
    PLoS One

19. LIANG S, Zhou S, Tang Y, Xiao M, et al
    Identification of the oxidation stress-related gene signatures and functional verification of MINK1 in prostate cancer cells.
    PLoS One. 2026;21:e0350334.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. WANG X, Liu W, Yang J, Tien JC, et al
    A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2537437123.
    PubMed         Abstract available
    
    

    
    Prostate

21. FALKENBACH F, Longoni M, Marmiroli A, Chi Le Q, et al
    Years of Life Lost in Incidental Prostate Cancer.
    Prostate. 2026 Jul 8. doi: 10.1002/pros.70222.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

22. CHEN IA, Chang RI, Yu CC, Lin TP, et al
    Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study.
    Ther Adv Urol. 2026;18:17562872261463076.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum